The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H.
 
April K.S. Salama
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Iovance Biotherapeutics; Pfizer; Regeneron
Research Funding - Ascentage Pharma (Inst); Bristol-Myers Squibb (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Merck (Inst); Olatec (Inst); Regeneron (Inst); Replimune (Inst); Seagen (Inst)
 
Victoria Wang
No Relationships to Disclose
 
Erin Renee Macrae
No Relationships to Disclose
 
Jong-In Park
No Relationships to Disclose
 
Helen X. Chen
No Relationships to Disclose
 
Robert James Gray
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Genomic Health (Inst); GlaxoSmithKline (Inst); Janssen-Ortho (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Sanofi (Inst); Sequenta (Inst); Syndax (Inst); Takeda (Inst)
 
Lisa McShane
No Relationships to Disclose
 
Lawrence Rubinstein
No Relationships to Disclose
 
P. Mickey Williams
Research Funding - Illumina (Inst)
Patents, Royalties, Other Intellectual Property - I was a co-inventor of the DLBCL cell of origin patent recently filed by the NIH
 
Stanley R. Hamilton
Research Funding - CytoImmune Therapeutics (Inst); Intima (Inst); Iovance Biotherapeutics (Inst); Minerva Biotechnologies (Inst)
 
Deborah Kay Armstrong
Consulting or Advisory Role - Johnson & Johnson/Janssen; Teon Therapeutics
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Pfizer (Inst); Syndax (Inst)
Other Relationship - AstraZeneca; AstraZeneca; AstraZeneca
 
James V. Tricoli
No Relationships to Disclose
 
Barbara A. Conley
No Relationships to Disclose
 
Carlos L. Arteaga
Stock and Other Ownership Interests - Provista Diagnostics
Consulting or Advisory Role - Arvinas; Astrazeneca; Athenex; Daiichi Sankyo; Immunomedics; Lilly; Merck; Novartis; Origimed; Puma Biotechnology; Sanofi; Taiho Pharmaceutical
Research Funding - Lilly; Pfizer
Other Relationship - Susan G. Komen for the Cure
(OPTIONAL) Uncompensated Relationships - Susan G. Komen for the Cure
 
Lyndsay Harris
Employment - Jessa Home Hospice (I)
Patents, Royalties, Other Intellectual Property - Philips Healthcare
 
Peter J. O'Dwyer
Research Funding - Amgen (Inst); Array BioPharma (Inst); BBI Healthcare (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Lilly/ImClone (Inst); Minneamrita Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); syndax (Inst); Taiho Pharmaceutical (Inst)
 
Alice P. Chen
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst)
 
Keith Flaherty
Leadership - Clovis Oncology; Kinnate Biopharma; Scorpion Therapeutics; Strata Oncology
Stock and Other Ownership Interests - Alterome Therapeutics; ALX Oncology; Apricity Health; Checkmate Pharmaceuticals; Clovis Oncology; FOGPharma; Kinnate Biopharma; Loxo; Monopteros Therapeutics; Nextech Invest; Oncoceutics; PIC Therapeutics; PreDICTA; Scorpion Therapeutics; Soley Therapeutics; Strata Oncology; Transcode Therapeutics; Tvardi Therapeutics; Vibliome Therapeutics; X4 Pharma; xCures
Consulting or Advisory Role - Debiopharm Group; Immagene; Karkinos Healthcare; Lilly; Novartis; OmRx Oncology; Oncoceutics; Quanta Therapeutics; Takeda; Tvardi Therapeutics